Boston University School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Outline a plan to proactively identify and remove barriers for health maintenance services and medication access in underserved patients with AA and/or AD.Īccreditor Disclosure of Conflicts of Interest Policyīoston University School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies.Recognize the potential place in therapy and monitoring aspects for the emerging agents in AA and AD in order to effectively engage patients in shared decision-making for their treatment plan.
#Peter lio dermatology trial
#Peter lio dermatology Activator
Our experts discuss the connection between AD and AA and compare/contrast their differences the challenges surrounding the available treatments for AD and AA, with a large unmet need for alternative and more effective therapies with a good safety profile for long-term use how the Janus kinase (JAK)-signal transducer activator of transcription pathways have an important role in the pathogenesis of AD and AA the latest clinical trial efficacy, safety, and tolerability data of available and emerging oral JAK inhibitors currently under investigation for AD and AA and the potential place in therapy and monitoring aspects for the emerging agents in AD and AA.įurthermore, the experts discuss how the health disparities of patients with AA and/or AD leads to lower medication access and they explore the unique role of the pharmacist in providing education and obtaining prior authorization to medications for patients with AA and/or AD. Their perspectives will provide insight into the daily challenges and quality of life issues that can occur while living with AD and AA. Also included are brief vignettes of actual patient interviews. This activity provides targeted education to community pharmacists and managed health care professionals for the emerging therapies on the horizon in moderate-to-severe atopic dermatitis (AD) and alopecia areata (AA).
This activity is supported by an independent educational grant from Pfizer. Getting to Know the New JAKs on the Block: Pharmacy-Focused Insights for Atopic Dermatitis and Alopecia Areata Provided by Boston University School of Medicine and The University of Rhode Island College of Pharmacy.